Bessemer Group
VKTX icon

Bessemer Group’s Viking Therapeutics VKTX Stock Holding History

Bessemer Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Sell
1,400
-1,000
-42% -$32.3K ﹤0.01% 1666
2026
Q1 		$78K Buy
+2,400
New +$77.1K ﹤0.01% 1557

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bessemer Group's VKTX Position: Q2 2026 in Review

Bessemer Group reduced its Viking Therapeutics (VKTX) stake by 42% in Q2 2026, selling an estimated $32.3K and leaving 1,400 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #1666.

Bessemer Group first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $78K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Bessemer Group held 1,400 shares of Viking Therapeutics worth $55K as of Q2 2026.
  • Bessemer Group sold 1,000 Viking Therapeutics shares in Q2 2026, an estimated $32.3K.
  • Viking Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1666 holding.
  • Bessemer Group first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bessemer Group's Viking Therapeutics position peaked at $78K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.